• Gubra posted H1 2026 revenue of DKK 126.3 million, down 95% year on year, while operating loss widened to DKK 122.9 million.
• Biotech revenue fell 99% to DKK 30 million, driving a swing to an EBIT loss of DKK 120 million from profit.
• CRO revenue slipped 9% to DKK 96.4 million as EBIT dropped to DKK 1.5 million; profitability was described as stabilized.
• Boehringer Ingelheim started Phase 2 of BI 3034701, triggering a EUR 10 million milestone; AbbVie’s ABBV-295 Phase 2 start is expected imminently.
• Guidance stayed unchanged, with Biotech total costs seen at DKK 330-360 million and CRO external revenue growth of 0-10%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.